Opendata, web and dolomites

Oximonitor

The first portable monitoring medical device providing accurate prognosis for patients with circulatory failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oximonitor project word cloud

Explore the words cloud of the Oximonitor project. It provides you a very rough idea of what is the project "Oximonitor" about.

fingerprint    monitoring    collecting    dead    software    start    enormous    treatment    first    sublingually    individuals    inability    predict    2017    exemplified    specialists    accurately    invasive    collects    machine    generating    financial    2023    body    o2    platform    35    sent    mlab    interpretation    proof    worldwide    billion    count    effectiveness    creates    expand    societal    patients    viability    membrane    clinical    monitors    costing    ecmo    care    decision    patented    sepsis    quantifying    cagr    17    cloud    dashboard    conjunctiva    point    manner    profit    patient    site    learning    odi    life    cardiac    data    75    recover    validated    34    skin       millions    acute    clab    neonatal    cells    oximonitor    hardware    survivors    health    computing    circulatory    22    company    clinically    microcirculatory    roi    likewise    staff    surface    bedside    ip    incorporates    symptom    optical    12    poc    400    sufficient    39    2022    cumulative    extracorporeal    report    market    respiratory    back    function    medical    asphyxia    norwegian    heart    oxygenation   

Project "Oximonitor" data sheet

The following table provides information about the project.

Coordinator
ODI MEDICAL AS 

Organization address
address: OSLO SCIENCE PARK, GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website https://odimedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ODI MEDICAL AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Microcirculatory failure (the inability to deliver sufficient O2 to the cells of the body), is a symptom from several health conditions affecting millions of individuals worldwide (e.g. heart failure, neonatal asphyxia or sepsis). The societal and financial impact of these conditions is enormous, as exemplified by patients in need of cardiac and respiratory support (such as extracorporeal membrane oxygenation life support or ECMO), with only 17% of survivors, while costing up to 1.35 M€ for a 1-year treatment. Specialists cannot predict if these patients are clinically dead or can recover because available medical devices do not allow to monitoring patient´s microcirculatory function. To solve this, at ODI Medical (a Norwegian start-up company) we have developed OXIMONITOR, the first-ever proof-of-concept validated, patented and non-invasive point of care (POC) integrated platform used bedside that accurately monitors microcirculatory function by quantifying O2 delivery and allows to assess the effectiveness of the patient´s treatment of choice, all in a user-friendly manner. OXIMONITOR incorporates: (1) The mLab hardware which creates an “optical fingerprint” of the patient’s circulatory function by collecting data from the surface of the patient’s skin, the conjunctiva or even sublingually. (2) The cLab; a Cloud computing software based on machine learning technology that collects and analyses the data generating the patient´s interpretation report, which is sent back to the clinical site through a user-friendly dashboard for decision-making. The market of cardiac monitoring (our first clinical application) will reach €22 billion by 2022 at a CAGR of 3.9% (2017-2022). With OXIMONITOR we will contribute to the viability of our company, generating a cumulative profit of 34.39 M€ (ROI of 12.75) and growing our staff count 400% by 2023. Likewise, the IP generated by this project will allow us to expand the number of clinical applications using our platform.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIMONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIMONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ARON (2020)

Assay-Ready Organ Network

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

TANDEM (2019)

Tuneable Acoustic Noise DampEning Material

Read More